Enruining® is the commercial brand name of Dexrazoxane for Injection, a cardioprotective agent developed by Gland Pharma Limited. It acts as a free radical scavenger and iron chelator, reducing anthracycline-induced cardiac toxicity by preventing the formation of iron-doxorubicin complexes that…
Imbruvica® is the commercial brand name of Ibrutinib Capsules, an orally active Bruton’s tyrosine kinase (BTK) inhibitor developed by Pharmacyclics. It covalently binds to BTK, blocking B-cell receptor signaling pathways to inhibit B-cell proliferation and survival. Main IndicationsTreatment of chronic…
TAGRISSO® is the commercial brand name of Osimertinib Mesylate Tablets, an orally active third-generation EGFR tyrosine kinase inhibitor developed by AstraZeneca. It selectively inhibits EGFR activating mutations and the T790M resistance mutation, blocking downstream signaling pathways to suppress tumor cell…
Zavesca® is the commercial brand name of Miglustat Capsules, an orally active glucosylceramide synthase inhibitor developed by Janssen. It reduces the synthesis of glycosphingolipids, thereby decreasing the accumulation of toxic substrates in lysosomes. Main IndicationsTreatment of mild to moderate type…
Tuoyi® is the Chinese commercial brand name of Toripalimab Injection, a humanized anti-PD-1 monoclonal antibody developed by Shanghai Junshi Biosciences. It blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, restoring the immune system’s ability to recognize and kill tumor…
VYLOY® is the commercial brand name of Zolbetuximab for Injection, a chimeric monoclonal antibody against Claudin 18.2 developed by Astellas Pharma. It binds to Claudin 18.2 on tumor cells, mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to kill…
Welidx™ is the commercial brand name of Belzutifan Film-coated Tablets, an orally active hypoxia-inducible factor 2α (HIF-2α) inhibitor developed by Bigbear Pharmaceutical. It binds to HIF-2α and blocks its interaction with HIF-1β, thereby inhibiting the transcription of genes involved in…
Welireg® is the commercial brand name of Belzutifan Tablets, an orally active hypoxia-inducible factor 2α (HIF-2α) inhibitor developed by MSD. It binds to HIF-2α and inhibits its heterodimerization with HIF-1β, thereby suppressing the transcription of genes involved in angiogenesis, cell…
Emblaveo® is the commercial brand name of Aztreonam and Avibactam Sodium for Injection, a combination antibacterial drug developed by Pfizer. It consists of aztreonam (a monobactam antibiotic) and avibactam (a β-lactamase inhibitor), used to treat infections caused by Gram-negative bacteria…
Afinitor® is the commercial brand name of Everolimus Tablets, an orally active mTOR inhibitor developed by Novartis. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway, thereby suppressing tumor cell proliferation, angiogenesis, and metabolism. Main IndicationsTreatment of advanced renal…